FDA Advisory committee doctors discuss opioid labeling

TL;DR

FDA approves opioids despite doubts from scientists and clinicians, with potential to change labeling for safety.

Transcript

the FDA continues to allow these drugs such as oxycontin to be manufactured and marketed and labeled as being effective for for long-term chronic ease when the majority of scientists clinicians around the country that that working in this area really don't believe that anymore but yet the FDA with the help of your committees has approved opioid aft... Read More

Key Insights

• 👍 FDA approves opioids despite expert doubts.
• ❓ Advisory Committee opinions not always followed.
• 🛟 Revisiting opioid safety standards could save lives.
• 🎚️ Resistance at various levels hinders regulatory changes.
• 🦺 FDA assessment of safety and efficacy under scrutiny.
• ❓ Potential for reducing opioid promotion and misuse.
• 🪡 Need for bold decisions to address opioid crisis.

Questions & Answers

Q: Why does the FDA approve opioids for long-term use despite doubts?

The FDA continues to approve opioids based on its own assessment of safety and efficacy, which may not align with expert opinions. Changing labeling standards could address this discrepancy.

Q: What power does the Advisory Committee have in FDA decisions?

While the Advisory Committee can provide opinions, the FDA ultimately makes decisions independently, sometimes disregarding expert advice. This lack of alignment raises concerns about regulatory processes.

Q: What obstacles prevent the FDA from changing opioid labeling?

Resistance at various levels, including the Advisory Committee, advocacy groups, and constituencies, hinders potential changes. Reinvestigating historical decisions and taking a bold stance may be necessary but challenging.

Q: How could revisiting opioid safety standards benefit public health?

Reevaluating safety standards could save lives by reducing unnecessary opioid use, promoting safer alternatives, and addressing the ongoing opioid crisis.

Summary & Key Takeaways

• FDA approves opioids despite skepticism from experts.

• Advisory Committee opinions not always followed by FDA.

• Call for revisiting opioid safety standards to save lives.